The dollar amount is too small to signal negative conviction. Monitor for any larger insider sales or a pattern of sustained selling by multiple C-suite officers in coming weeks; absent that, this cluster is noise.
Price Chart
Executive Summary
Two senior executives at Enliven Therapeutics (CMO and CFO) conducted open-market sales totaling ~$323K within a 7-day window. The CMO also exercised and sold derivative shares, while the CFO's sale was a straightforward open-market disposition. Relative to the company's market cap (~$1.7B based on ~34M shares at ~$50), this represents ~0.02% — a trivial amount. The cluster is small in dollar terms and likely reflects routine portfolio diversification or tax planning, not a material negative signal.
Key Financial Metrics
Key Facts
- CMO Helen Louise Collins sold 2,916 shares at $50.03, 1,844 shares at $50.71, and 240 shares at $51.48 — total ~$252K in open-market sales.
- CMO also exercised 5,000 derivative shares at $2.48 and 5,000 at $0 (non-cash) — these are non-economic events.
- CFO Benjamin Hohl sold 3,500 shares at $50.03 for ~$177K.
- Total cluster value of ~$323K represents ~0.02% of Enliven's estimated market cap — well below the 0.1% materiality threshold.
- No 10b5-1 plan indication is noted, but the small size and senior-executive pattern (CMO + CFO) are consistent with routine post-vesting diversification.
Financial Impact
Total insider sales of ~$323K, representing ~0.02% of market cap — immaterial.
Risk Factors
- CMO and CFO both selling in the same window could be misinterpreted by the market as a negative signal, though the dollar amount is trivial.
- No recent company-specific catalysts (earnings, pipeline data) are referenced in the filing — the sales appear unconnected to any material event.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ELVN-1790025852975 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $41.80 | awaiting T+5 | — | $43.69 (+4.52%) |
Oct 21, 2026 6d ago | Insider Cluster | $41.93 | awaiting T+5 | — | $43.69 (+4.20%) |
Oct 19, 2026 8d ago | 144 | $41.25 $43.69 | ▲ +5.92% | ▲ +5.84% | $43.69 (+5.92%) |
Oct 16, 2026 11d ago | 3 | $38.70 $41.49 | ▲ +7.21% | ▲ +7.35% | $43.69 (+12.89%) |
Oct 14, 2026 13d ago | 8-K | $39.33 $41.93 | ▲ +6.61% | ▲ +7.63% | $43.69 (+11.09%) |
Sep 21, 2026 5w ago | Insider Cluster | $48.19 $46.51 | ▼ −3.49% | ▼ −2.30% | $43.69 (−9.34%) |
Sep 4, 2026 7w ago | 144 | $59.32 $54.43 | ▼ −8.24% | ▼ −7.03% | $43.69 (−26.35%) |
Aug 19, 2026 9w ago | Insider Cluster | $58.97 $60.50 | ▲ +2.59% | ▲ +1.48% | $43.69 (−25.91%) |
Aug 9, 2026 11w ago | Institutional Cluster | $59.42 $59.54 | ▲ +0.19% | ▲ +0.24% | $43.69 (−26.47%) |
Jul 21, 2026 14w ago | Insider Cluster | $52.85 $52.97 | ▲ +0.23% | ▲ +2.63% | $43.69 (−17.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers